These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35067961)

  • 1. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
    Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Complete response of an anaplastic thyroid carcinoma patient with
    Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
    Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
    Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [No Abstract]   [Full Text] [Related]  

  • 7. Neoadjuvant treatment with lenvatinib and pembrolizumab in a
    Barbaro D; Forleo R; Profilo MA; Lapi P; Giani C; Torregrossa L; Macerola E; Materazzi G
    Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski CC; Cabanillas ME; Boran A; Ilankumaran P; Burgess P; Romero Salas T; Keam B
    Ann Oncol; 2022 Apr; 33(4):406-415. PubMed ID: 35026411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
    Califano I; Smulever A; Jerkovich F; Pitoia F
    Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
    Maurer E; Eilsberger F; Wächter S; Riera Knorrenschild J; Pehl A; Holzer K; Neubauer A; Luster M; Bartsch DK
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.
    Hamidi S; Dadu R; Zafereo ME; Ferrarotto R; Wang JR; Maniakas A; Gunn GB; Lee A; Spiotto MT; Iyer PC; Sousa LG; Akhave NS; Ahmed S; Learned KO; Lu C; Lai SY; Williams M; Hosseini SM; Busaidy NL; Cabanillas ME
    JAMA Oncol; 2024 Sep; 10(9):1264-1271. PubMed ID: 38990526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer.
    Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
    J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
    [No Abstract]   [Full Text] [Related]  

  • 13. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
    Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
    Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
    Cabanillas ME; Ferrarotto R; Garden AS; Ahmed S; Busaidy NL; Dadu R; Williams MD; Skinner H; Gunn GB; Grosu H; Iyer P; Hofmann MC; Zafereo M
    Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
    Chen TY; Lorch JH; Wong KS; Barletta JA
    Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature.
    Arıkan R; Telli TA; Demircan NC; Başoğlu T; Ercelep Ö; Atasoy BM; Özgüven S; Dane F; Yumuk PF
    Curr Probl Cancer; 2021 Apr; 45(2):100668. PubMed ID: 33127167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.
    Locati LD; Colombo E; Dedecjus M; de la Fouchardière C; Sents W; Bongiovanni M; Netea-Maier R
    Eur J Cancer; 2023 Feb; 180():146-154. PubMed ID: 36599182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anaplastic thyroid carcinoma : new therapeutic approaches].
    Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
    Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.